Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells

Stem Cells

Volumn 27, Issue 11, 2009, Pages 2865-2874

  Zangi, Lior ^a   Margalit, Raanan ^a   Reich Zeliger, Shlomit ^a   Bachar Lustig, Esther ^a   Beilhack, Andreas ^c   Negrin, Robert ^b   Reisner, Yair ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cell transplantation; Cellular therapy; Immunogenicity; Mesenchymal stem cells

Indexed keywords

HERMES ANTIGEN; INTERLEUKIN 2 RECEPTOR BETA; L SELECTIN; LUCIFERASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELL TRANSPLANTATION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; EXPERIMENT; FEMALE; FIBROBLAST; GRAFT REJECTION; HAPLOTYPE; IMAGING; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; MALE; MESENCHYME CELL; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PHENOTYPE; RECIPIENT; STROMA CELL; SURVIVAL TIME; TRANSGENIC MOUSE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; MICE, TRANSGENIC; STROMAL CELLS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

MUS;

EID: 72849151523     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.217     Document Type: Article

References (56)

1. Fridenshtein AIa. [Stromal bone marrow cells and the hematopoietic microenvironment]. Arkh Patol 1982;44:3-11.
2. Dekel B, Zangi L, Shezen E et al. Isolation and characterization of nontubular sca-1+lin- multipotent stem/progenitor cells from adult mouse kidney. J Am Soc Nephrol 2006;17:3300-3314. (Pubitemid 44865273)
3. Devine SM, Cobbs C, Jennings M et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003;101:2999-3001. (Pubitemid 36857986)
4. Gao J, Dennis JE, Muzic RF et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001;169:12-20. (Pubitemid 32437040)
5. Tse WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003;75:389-397.
6. Zhang W, Ge W, Li C et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004;13:263-271. (Pubitemid 38738368)
7. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-1822. (Pubitemid 40223708)
8. Beyth S, Borovsky Z, Mevorach D et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005;105:2214-2219. (Pubitemid 40731815)
9. Le Blanc K, Rasmusson I, Gotherstrom C et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004;60:307-315. (Pubitemid 39141263)
10. Arikawa T, Omura K, Morita I. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol 2004;200:400-406. (Pubitemid 39006932)
11. Meisel R, Zibert A, Laryea M et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-4621. (Pubitemid 38745993)
12. Zhou HP, Yi DH, Yu SQ et al. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc 2006;38:3046-3051.
13. Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002;99:8932-8937.
14. Ryan JM, Barry FP, Murphy JM et al. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (London) 2005;2:8.
15. Ko̧c ON, Day J, Nieder M et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002;30:215-222. (Pubitemid 35023593)
16. Arinzeh TL, Peter SJ, Archambault MP et al. Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am 2003;85-A:1927-1935. (Pubitemid 37259728)
17. Fouillard L, Bensidhoum M, Bories D et al. Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma. Leukemia 2003;17:474-476. (Pubitemid 36266932)
18. Cahill RA, Jones OY, Klemperer M et al. Replacement of recipient stromal/mesenchymal cells after bone marrow transplantation using bone fragments and cultured osteoblast-like cells. Biol Blood Marrow Transplant 2004;10:709-717. (Pubitemid 39272875)
19. Ringdén O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81:1390-1397. (Pubitemid 43847148)
20. Ringdén O, Uzunel M, Sundberg B et al. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 2007;21:2271-2276. (Pubitemid 350011699)
21. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007;262:509-525. (Pubitemid 47620502)
22. Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-313.
23. Lee ST, Jang JH, Cheong JW et al. Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br J Haematol 2002;118:1128-1131.
24. Djouad F, Plence P, Bony C et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102:3837-3844. (Pubitemid 37409409)
25. Eliopoulos N, Stagg J, Lejeune L et al. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 2005;106:4057-4065. (Pubitemid 41775910)
26. Sudres M, Norol F, Trenado A et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006;176:7761-7767. (Pubitemid 43849077)
27. Inoue S, Popp FC, Koehl GE et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006;81:1589-1595. (Pubitemid 43890897)
28. Nauta AJ, Westerhuis G, Kruisselbrink AB et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006;108:2114-2120. (Pubitemid 44395028)
29. Wan CD, Cheng R, Wang HB et al. Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in a rat orthotopic liver transplantation model. Hepatobiliary Pancreat Dis Int 2008;7:29-33. (Pubitemid 351247053)
30. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007;110:3499-3506. (Pubitemid 350159613)
31. Kotobuki N, Katsube Y, Katou Y et al. In vivo survival and osteogenic differentiation of allogeneic rat bone marrow mesenchymal stem cells (MSCs). Cell Transplant 2008;17:705-712.
32. Beilhack A, Schulz S, Baker J et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 2005;106:1113-1122.
33. Meirelles Lda S, Nardi NB. Murine marrow-derived mesenchymal stem cell: Isolation, in vitro expansion, and characterization. Br J Haematol 2003;123:702-711.
34. Zangi L, Rivkin R, Kassis I et al. High-yield isolation, expansion, and differentiation of rat bone marrow-derived mesenchymal stem cells with fibrin microbeads. Tissue Eng 2006;12:2343-2354. (Pubitemid 44734992)
35. Reich-Zeliger S, Gan J, Bachar-Lustig E et al. Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. II. Deletion of effector cells by Fas-Fas ligand apoptosis. J Immunol 2004;173:6660-6666. (Pubitemid 39541050)
36. Steiner D, Brunicki N, Bachar-Lustig E et al. Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: Synergism with veto cells and rapamycin. Exp Hematol 2006;34:802-808. (Pubitemid 43737090)
37. rd party CD8 T cells in allogeneic bone marrow transplantation. Blood (ASH Annual Meeting Abstracts) Nov 2008;112:2323.
38. Niederkorn JY, Peeler JS, Ross J et al. The immunogenic privilege of corneal allografts. Reg Immunol 1989;2:117-124.
39. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838-3843. (Pubitemid 34534559)
40. Silva WA Jr., Covas DT, Panepucci RA et al. The profile of gene expression of human marrow mesenchymal stem cells. Stem Cells 2003;21:661-669. (Pubitemid 37329159)
41. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: Effects of dexamethasone and IL-1 alpha. J Cell Physiol 1996;166:585-592.
42. Rasmusson I, Ringden O, Sundberg B et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76:1208-1213. (Pubitemid 37339646)
43. Ryan JM, Barry F, Murphy JM et al. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007;149:353-363. (Pubitemid 47063057)
44. Hakamata Y, Murakami T, Kobayashi E. "Firefly rats" as an organ/cellular source for long-term in vivo bioluminescent imaging. Transplantation 2006;81:1179-1184.
45. Parekkadan B, Tilles AW, Yarmush ML. Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells 2008;26:1913-1919.
46. Zappia E, Casazza S, Pedemonte E et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing Tcell anergy. Blood 2005;106:1755-1761. (Pubitemid 41208591)
47. Stagg J. Immune regulation by mesenchymal stem cells: Two sides to the coin. Tissue Antigens 2007;69:1-9. (Pubitemid 46025333)
48. Stagg J, Pommey S, Eliopoulos N et al. Interferon-gamma-stimulated marrow stromal cells: A new type of nonhematopoietic antigen-presenting cell. Blood 2006;107:2570-2577. (Pubitemid 43348704)
49. Cho PS, Messina DJ, Hirsh EL et al. Immunogenicity of umbilical cord tissue derived cells. Blood 2008;111:430-438.
50. Chan JL, Tang KC, Patel AP et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 2006;107:4817-4824.
51. Liu H, Kemeny DM, Heng BC et al. The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. J Immunol 2006;176:2864-2871. (Pubitemid 43306946)
52. Minguell JJ, Erices A. Mesenchymal stem cells and the treatment of cardiac disease. Exp Biol Med (Maywood) 2006;231:39-49. (Pubitemid 43063975)
53. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371:1579-1586.
54. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441. (Pubitemid 38586721)
55. Al-Toma A, Mulder CJ. Review article: Stem cell transplantation for the treatment of gastrointestinal diseases-current applications and future perspectives. Aliment Pharmacol Ther 2007;26 Suppl 2:77-89. (Pubitemid 350233323)
56. Dazzi F, van Laar JM, Cope A et al. Cell therapy for autoimmune diseases. Arthritis Res Ther 2007;9:206.